Cargando…

Neonatal BCG Vaccination Reduces Interferon-γ Responsiveness to Heterologous Pathogens in Infants From a Randomized Controlled Trial

BACKGROUND: BCG vaccination has beneficial nonspecific (heterologous) effects that protect against nonmycobacterial infections. We have previously reported that BCG vaccination at birth alters in vitro cytokine responses to heterologous stimulants in the neonatal period. This study investigated hete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freyne, Bridget, Messina, Nicole L, Donath, Susan, Germano, Susie, Bonnici, Rhian, Gardiner, Kaya, Casalaz, Dan, Robins-Browne, Roy M, Netea, Mihai G, Flanagan, Katie L, Kollmann, Toby, Curtis, Nigel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289544/ https://www.ncbi.nlm.nih.gov/pubmed/31990350 http://dx.doi.org/10.1093/infdis/jiaa030

Ejemplares similares

Study protocol for the Melbourne Infant Study: BCG for Allergy and Infection Reduction (MIS BAIR), a randomised controlled trial to determine the non-specific effects of neonatal BCG vaccination in a low-mortality setting
por: Messina, Nicole L, et al.
Publicado: (2019)

Innate immune responses following Kawasaki disease and toxic shock syndrome
por: Chen, Katherine Y. H., et al.
Publicado: (2018)

Heterologous Immunological Effects of Early BCG Vaccination in Low-Birth-Weight Infants in Guinea-Bissau: A Randomized-controlled Trial
por: Jensen, Kristoffer Jarlov, et al.
Publicado: (2015)

Use of a paediatric advice line for parents of infants recruited to a randomised controlled trial
por: Chan, Joyce, et al.
Publicado: (2023)

Efficacy of BCG Vaccination Against Respiratory Tract Infections in Older Adults During the Coronavirus Disease 2019 Pandemic
por: Moorlag, Simone J C F M, et al.
Publicado: (2022)

Considering BCG vaccination to reduce the impact of COVID-19
por: Curtis, Nigel, et al.
Publicado: (2020)

Neonatal BCG vaccination is associated with a long-term DNA methylation signature in circulating monocytes
por: Bannister, Samantha, et al.
Publicado: (2022)

Off‐target effects of bacillus Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2: implications for protection against severe COVID‐19
por: Messina, Nicole L, et al.
Publicado: (2022)

Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers
por: Pittet, Laure F., et al.
Publicado: (2023)

BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial
por: Prentice, Sarah, et al.
Publicado: (2021)

The Contribution of Non-Conventional T Cells and NK Cells in the Mycobacterial-Specific IFNγ Response in Bacille Calmette-Guérin (BCG)-Immunized Infants
por: Zufferey, Christel, et al.
Publicado: (2013)

Assessing the effect of BCG revaccination on long-term mortality
por: Netea, Mihai G, et al.
Publicado: (2021)

BCG Vaccination Induces Different Cytokine Profiles Following Infant BCG Vaccination in the UK and Malawi
por: Lalor, Maeve K., et al.
Publicado: (2011)

The safety of co-administration of Bacille Calmette-Guérin (BCG) and influenza vaccines
por: Villanueva, Paola, et al.
Publicado: (2022)

Heterologous effects of infant BCG vaccination: potential mechanisms of immunity
por: Butkeviciute, Egle, et al.
Publicado: (2018)

Revaccination with Bacille Calmette-Guérin (BCG) is associated with an increased risk of abscess and lymphadenopathy
por: Villanueva, Paola, et al.
Publicado: (2022)

BNT162b2 COVID-19 vaccination in children alters cytokine responses to heterologous pathogens and Toll-like receptor agonists
por: Noé, Andrés, et al.
Publicado: (2023)

BCG-induced trained immunity: can it offer protection against COVID-19?
por: O’Neill, Luke A. J., et al.
Publicado: (2020)

BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial)
por: Pittet, Laure F, et al.
Publicado: (2021)

Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants
por: Jäger, Michael, et al.
Publicado: (2023)

Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
por: Harris, Stephanie A., et al.
Publicado: (2014)

Recombinant BCG ΔureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine Responses
por: Desel, Christiane, et al.
Publicado: (2011)

Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study
por: Costa Clemens, Sue Ann, et al.
Publicado: (2022)

Mycobacterium tuberculosis-specific cytokine biomarkers for the diagnosis of childhood TB in a TB-endemic setting
por: Sudbury, Eva L., et al.
Publicado: (2019)

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study
por: Goldstein, Neil, et al.
Publicado: (2020)

Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines
por: Atıcı, Serkan, et al.
Publicado: (2023)

Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults
por: Roa, Camilo C, et al.
Publicado: (2023)

Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults
por: Rakshit, Srabanti, et al.
Publicado: (2022)

Neonatal BCG vaccination is associated with enhanced T-helper 1 immune responses to heterologous infant vaccines
por: Libraty, Daniel H., et al.
Publicado: (2014)

Gene Expression and Cytokine Profile Correlate With Mycobacterial Growth in a Human BCG Challenge Model
por: Matsumiya, Magali, et al.
Publicado: (2015)

Long-Lasting Transcriptional Changes in Circulating Monocytes of Acute Q Fever Patients
por: Raijmakers, Ruud Ph, et al.
Publicado: (2019)

Interpreting the Results of Trials of BCG Vaccination for Protection Against COVID-19
por: Noble, Christie C A, et al.
Publicado: (2023)

Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial
por: Poh, Xuan Ying, et al.
Publicado: (2022)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Genome-Wide Association Study Identifies Novel Colony Stimulating Factor 1 Locus Conferring Susceptibility to Cryptococcosis in Human Immunodeficiency Virus-Infected South Africans
por: Kannambath, Shichina, et al.
Publicado: (2020)

Immunometabolic Pathways in BCG-Induced Trained Immunity
por: Arts, Rob J.W., et al.
Publicado: (2016)

The influence of the gut microbiome on BCG-induced trained immunity
por: Stražar, Martin, et al.
Publicado: (2021)

Anti-mycobacterial activity correlates with altered DNA methylation pattern in immune cells from BCG-vaccinated subjects
por: Verma, Deepti, et al.
Publicado: (2017)

Immune Response Kinetics Following a Third Heterologous BNT162b2 Booster Dose After Primary 2-Dose ChAdOx1 Vaccination in Relation to Omicron Breakthrough Infection: A Prospective Nationwide Cohort Study in South Korea
por: Ahn, Jin Young, et al.
Publicado: (2023)

STUDIES ON THE HETEROLOGOUS IMMUNOGENICITY OF A METHANOL-INSOLUBLE FRACTION OF ATTENUATED TUBERCLE BACILLI (BCG) : I. ANTIMICROBIAL PROTECTION
por: Weiss, David W., et al.
Publicado: (1964)

Cannot write session to /tmp/vufind_sessions/sess_tsq14j1p66bm0otr447dp28j7o